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Introduction
Percutaneous transluminal procedures represent
an increasingly used and effective treatment of pe-
ripheral artery disease (PAD) [1, 2]. The introduc-
tion of self-expanding nitinol stents allowed treat-
ment of long lesions/occlusions of the superficial
femoral arteries (SFA) improving the long-term re-
sults of the endovascular revascularization, with pri-
mary patency in SFA occlusions up to 80% at 2
years follow-up [3-5]. Antiplatelet therapy with
acetylsalicylic acid is indicated for all patients with
PAD undergoing peripheral transluminal angioplas-
ty, while dual antiplatelet therapy, associating clopi-
dogrel with aspirin, is suggested in clinical practice
as antithrombotic therapy after peripheral stent im-
plantation. In particular, dual antiplatelet therapy is
particularly recommended in high-risk patients with
lesions in the femoropopliteal segments and in the
smaller diameter tibial arteries [6-8]. SFA nitinol
stent thrombosis after discontinuing antiplatelet
therapy, although uncommon, is an urgent clinical
complication of acute limb ischaemia (ALI), neces-
sitating immediate percutaneous intervention.
Rheolytic thrombectomy (RT) with AngioJet®
(Possis Medical, Inc., Minneapolis, MN, USA) has
been previously approved by the Food and Drug Ad-
ministration for the treatment of acute thrombosis of
venous grafts and native coronary arteries. The An-
gioJet® system consists of a drive unit control con-
sole, a pump set and an AngioJet® spiroflex rapid
exchange rheolytic thrombectomy catheter. The lat-
ter is a dual lumen, sterile, single-use catheter de-
signed to remove thrombi from coronary conduits.
High velocity saline jets directed back into the
catheter create a localized low-pressure zone at the
distal tip (Bernoulli principle), which results in the
suction, break-up and removal of thrombus through
the outflow lumen.
During percutaneous transluminal coronary an-
gioplasty (PTCA) of venous grafts, RT has been
shown to be safe and its use has significantly im-
proved angiographic results, without increasing
mortality [9]. Conversely, data regarding the use of
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Thrombosis of superficial femoral artery (SFA) nitinol
stents or polytetrafluoroethylene (PTFE) femoropopliteal by-
pass grafts after discontinuation of antiplatelet therapy is an
emergent clinical challenge of acute limb ischemia (ALI), re-
quiring immediate percutaneous intervention. Currently,
there is no evidence-based approach for the management of
such complications. We describe the cases of two patients pre-
senting with ALI due to nitinol stent thrombosis after discon-
tinuation of antiplatelet therapy and the case of a patient pre-
senting with ALI due to PTFE femoropopliteal graft throm-
bosis in which limb salvage was obtained by AngioJet® rhe-
olytic thrombectomy and re-stenting. In both cases, the throm-
bus was successfully removed using the Possis AngioJet® me-
chanical thrombectomy catheter and percutaneous translumi-
nal angioplasty (PTA) was performed to recanalize two
femoropopliteal nitinol stents and a femoropopliteal PTFE
graft. In both cases, optimal angiographic result was obtained.
To the best of our knowledge, these are the first three cases re-
porting the use of the AngioJet rheolytic thrombectomy in
ALI due to stent or graft thrombosis. Taken together, these
cases suggest that AngioJet® rheolytic thrombectomy might
represent a novel effective strategy in the percutaneous treat-
ment of stent or graft thrombosis determining ALI.
Keywords: acute limb ischemia, AngioJet® rheolytic throm-
bectomy, stent thrombosis.
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this procedure in native coronary artery are contro-
versial and while one randomized study leaded in a
high volume center (Florence trial) showed the same
results obtained for venous grafts [10], Ali et al. [11]
demonstrated neither an improvement of angio-
graphic results nor an improvement of the mortality
by the RT.
Despite no randomized clinical trials support the
utility of AngioJet® in other districts, RT could be
potentially used during percutaneous transluminal
angioplasty (PTA) of other vessels, in particular of
femoro-popliteal arteries. Indeed, here we describe
the cases of three patients presenting with acute limb
ischemia due to nitinol stent or PTFE femoro-
popliteal graft thrombosis, in which limb salvage
was obtained by AngioJet rheolytic thrombectomy
and re-stenting.
The patients were admitted to our Department
due to severely reduced walking capacity, rest pedal
pain with or without ulcer toe, pointing out the di-
agnosis of ALI. All patients were aged 73±1years,
presented hypertension and hypercholesterolemia.
Two patients had rheumatoid arthritis and history of
previous PTA and stent implantation for total occlu-
sion of SFA, while one patient presented a history of
right femoro-popliteal PTFE by-bass for ALI fol-
lowed by PTA and stent implantation of the distal
anastomosis.
After the first procedure, all patients were dis-
charged with optimal dual antiplatelet therapy ex-
cepted for the second patient who referred history of
ASA allergy. Because of the onset of other clinical
conditions (see below), two patients discontinued the
antiplatelet therapy during the follow-up and present-
ed stent thrombosis which was successfully removed
using the Possis AngioJet® catheter. To the best of our
knowledge, these are the first three reports on the use
of the AngioJet® rheolytic thrombectomy in ALI for
stent or PTFE graft thrombosis.
Case Presentation
Patient 1
A 72-year-old woman with hypertension, hyper-
cholesterolemia and rheumatoid arthritis was admit-
ted to our Department complaining severely reduced
walking capacity (maximum walking distance <
than 20 meters), rest right pedal pain and ulcer toe,
suggesting the diagnosis of critical lower limb is-
chemia. At that time the patient’s therapy consisted
of atorvastatin 10 mg, ASA 175 mg, bisoprolol 2.5
mg, valsartan 160 mg and methotrexate 2.5 mg/die.
Autoimmunity evaluation on blood samples showed
increased IgG anti-cardiolipin levels in the absence
of IgM autoantibodies. Duplex ultrasound demon-
strated the occlusion of the proximal right superfi-
cial femoral artery. According to symptoms and
clinical signs, the patient was classified as Fontaine’s
stage IV.
Peripheral angiography confirmed the proximal
occlusion of SFA (TASC classification type C le-
sion). After heparin infusion and using crossover
technique, PTA with stent implantation of the SFA
and popliteal artery was performed (nitinol stents
Xpert 8.0x40 mm and 2 Protégé Everflex 7.0x120
mm and 6.0x120 mm), providing an optimal angio-
graphic result and a good runoff to distal vessels.
The patient received a loading dose of clopidogrel
(300 mg) P.O. and was discharged on dual an-
tiplatelet therapy (ASA 100 mg/die plus clopidogrel
75 mg/die) in addition to her homing therapy. Du-
plex ultrasound performed two days later showed
normal flow of treated segments and downstream.
Seven days after the procedure, the onset of gas-
trointestinal bleeding (Hb 8.70 g/dl) induced her pri-
mary care physician to stop her dual antiplatelet
medication. After 15 days, the patient returned to
our Department for rest pain and right ALI. Right
pedal pulse was absent. The peripheral angiography
showed acute stent thrombosis from the proximal
right SFA up to popliteal segment (Figure 1, A and B).
Thus, anticoagulation with heparin was immediate-
ly started and several attempts to open the occluded
stent were performed. First, a 0.035-inch J-shaped
Terumo stiff guide-wire was used to cross the
thrombotic occlusion and then multiple dilatations
of the stents within the SFA were performed with a
3.0x40 mm balloon catheter (Amphirion), without
any good result. Thus, we decided to operate a me-
chanical thrombectomy using the Possis AngioJet®
catheter (Figure 1C). As a result, mechanical aspira-
tion of the thrombus allowed a good angiographic
runoff and then two self-expandable stents (Dyna
Link 6.0x100 mm and Protégé Everflex 6.0x60.0
mm) were implanted. After the procedure, the pa-
tient reported that pain disappeared and control an-
giography of the treated arterial segment revealed an
optimal angiographic result and a good runoff to
patent vessels below the knee (Figure 1, D-E-F). At
1 year follow-up, the ulcer on her toe healed and no
stenotic lesions were found at colour Doppler ultra-
sound.
Patient 2
A 74-year-old woman with hypercholes-
terolemia, rheumatoid arthritis and a history of ASA
allergy was admitted to our Department with rest
pedal pain and duplex ultrasound evidence of left
proximal SFA occlusion (Fontaine’s stage III). Pe-
ripheral angiography confirmed the proximal occlu-
sion of SFA (TASC Classification type C). After he-
parin infusion, using crossover technique, PTA with
stent implantation in the left SFA and popliteal
artery was performed (2 nitinol stents, Protegè Ever-
flex 6.0x120 mm) obtaining a good angiographic re-
sult. The patient received a loading dose with clopi-
dogrel (300 mg) P.O. and she was discharged on
clopidogrel (75 mg/die) without ASA.
At 2-month follow-up, duplex ultrasound scan
showed a normal flow through the stents and the
downstream segments. The patient referred an im-
provement of walking capacity and the disappear-
ance of rest symptoms until 4 months later when she
returned to our Department for ALI. Notably, patient
never stopped antiplatelet therapy with clopidogrel.
Pedal pulses were absent and duplex ultrasound in-
dicated an acute thrombosis in the distal SFA/
popliteal segment. The angiography confirmed an
occlusion of the left SFA 4 cm before the previous
implanted stent, up to the upper border of patella
(the total length of thrombotic lesion was approxi-
mately 20 cm; Figure 2, A and B).
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Using crossover technique, PTA of the left SFA
was performed. Initially, a 0.035” J-shaped Terumo
guide-wire was passed through the thrombotic lu-
men up to the end of the obstruction; then multiple
PTAs were performed, using an Admiral Xtreme
Balloon Catheter 5.0x60 mm, without obtaining any
good result. Thus, the Possis AngioJet® catheter was
passed on the 0.014” guide-wire through the throm-
botic lumen (Figure 2C), and the thrombus was as-
pirated. Once previously stented vessel was re-
opened, the result was optimized with nitinol self-
expanding re-stenting using two Protégé Everflex
nitinol stents (6.0x150 mm and 6.0x100 mm), lead-
ing to satisfactory angiographic outcome (Figure 2,
D-E-F). A month after discharge, pain and walking
limitations disappeared. Twelve months later, colour
Doppler ultrasound showed patent stent segment
and normal flow pattern.
Patient 3
A 72-year-old man, with atrial fibrillation, hy-
percholesterolemia and history of right femoro-
popliteal PTFE bypass implantation for right ALI,
was admitted to our Department because of rest ped-
al pain and duplex ultrasound evidence of both left
proximal SFA and by-pass occlusion with distal col-
lateral flow (Fontaine’s stage III).
Peripheral angiography confirmed the proximal
occlusion of both SFA and the femoro-popliteal by-
pass. Moreover, a critical stenosis of the left external
iliac artery was found. In order to perform a PTA, 6F
long sheaths (Therumo Destination) were posi-
tioned, 5000 U.I. of heparin were administered in-
travenously and the PTFE graft was then passed
with a 0.035” J-Shaped Terumo stiff guide-wire.
The critical stenosis of external iliac artery was
treated with PTA and stent implantation (Complete
7x40 mm) followed by PTA and stenting of the dis-
tal graft anastomosis (Protégé Everflex 7x60 mm).
Final angiography revealed optimal result. The pa-
tient received a loading dose of clopidogrel (300
mg) P.O. and ASA (500 mg) i.v. and he was dis-
charged with clopidogrel (75 mg/die) and ASA (100
mg/die). Two months later, duplex ultrasounds scan
demonstrated a normal flow through the stents and
the downstream segments.
After the procedure, the patient was asympto-
matic for 4 months under dual antiplatelet therapy.
However, he was recommended to stop clopidogrel
and to start warfarin anticoagulation therapy in ad-
dition to ASA, in order to prevent thromboembolic
events because of the persistence of atrial fibrilla-
tion. Nevertheless, clopidogrel was incorrectly in-
terrupted before reaching therapeutic range of INR.
One month later, he returned to our Department for
ALI (Fontaine’s stage IV). Pedal pulses were absent
and duplex ultrasound showed acute thrombosis of
both right PTFE graft and previous implanted stent
at the distal anastomosis. Angiography confirmed
the complete occlusion of both by-pass and the pre-
viously deployed stent at the distal anastomosis
(Figure 3A). PTA of right PTFE by-pass was per-
formed by using the crossover technique. A 0.035”
J-shaped Terumo stiff guide-wire was crossed
Figure 1. - Proximal thrombotic occlusion of the left superficial femoral artery (A) and slow flow to the popliteal artery at angiography (B). C: AngioJet
catheter positioned in the left superficial femoral artery to remove thrombus. D, E, F: thrombus aspiration and vessel patency.
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through the lumen up to the distal end of the tibio-
peroneal trunks. Using an Admiral Xtreme Balloon
Catheter 6.0x40 mm multiple PTAs were performed
without reaching any good result. Furthermore, the
angiography showed multiple minus images, reveal-
ing thrombus persistence (Figure 3B). Thus, a me-
chanical thrombectomy using Possis AngioJet® was
performed using the Spiroflex catheter on a 0.014”
guide-wire obtaining an optimal result up to the dis-
tal segment of the by-pass. Finally, a new stent (ab-
solute Pro 7.0x60 mm) was implanted in the distal
femoral popliteal artery in order to reach a better
clinical outcome (Figure 3C). One month after dis-
charge, pain and walking limitations disappeared.
Six months later, colour Doppler ultrasound demon-
strated patent stent segment and a normal flow pat-
tern.
Discussion
The primary goals of ALI treatment are to re-
lieve ischemic pain and to prevent limb loss. Prima-
ry percutaneous revascularization with new nitinol
stents in association to dual antiplatelet therapy is
safe and improves late patency rates [1, 3, 5]. Here
we describe three cases of SFA stent thrombosis as
a consequence of inadequate or prematurely discon-
tinued dual antiplatelet therapy after SFA stenting. It
is important to emphasize that much of the support-
ing evidence for antiplatelet therapy after SFA stent-
ing is extrapolated from what is related to the coro-
nary circulation [6]. Dual antiplatelet therapy for
three to six months after PTA and nitinol stent place-
ment is usually recommended to prevent early stent
failure because of thrombosis at the intervention
site. Our patients were characterized by high-risk
metabolic-profile, with long peripheral lesions (type
C TASC classification) and, strikingly, two of them
were affected by rheumatoid arthritis, a chronic in-
flammatory disease associated with pro-athero-
thrombotic state. Notably, in this setting the dis-
charge of dual antiplatelet therapy for major bleed-
ing (case report 1) or a suboptimal antiplatelet ther-
apy for ASA allergy (case report 2) may have in-
duced the thrombotic event development following
the primary SFA stent placement. In addition, the
clinical case 3 reflects the different roles of antico-
agulation and antiplatelets drugs, and the key role of
reaching the therapeutic INR target.
Although it is well known that initial therapeutic
strategy for ALI aims at preventing thrombus prop-
agation and worsening of ischemia, which technique
should be considered the gold standard during ALI
caused by stent thrombosis is still uncertain. Data
from randomized studies suggest that catheter di-
rected-thrombolisys is associated to reduced mortal-
ity rate and to a less complex surgical procedure
when compared to surgical revascularization, de-
spite a higher rate of recurrent ischemia and risk of
amputation [12-15]. Several non-randomized stud-
ies validated the role of combined percutaneous en-
dovascular approach including mechanical throm-
bus aspiration, catheter thrombolysis, and percuta-
Figure 2. - Thrombotic occlusion of the right superficial femoral artery from the proximal edge of the previously implanted segment (A) to the distal
popliteal segment at angiography (B). C: positioning of the AngioJet catheter through the lesion. D, E, F: good angiographic result, with excellent 
vessel patency at the end of the procedure.
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neous transluminal angioplasty to treat acute and
sub-acute occlusions of native leg arteries [16].
Thus, percutaneous thrombectomy devices represent
a non-surgical alternative for the treatment of ALI
and they may be used together with fibrinolysis to
reduce time and dose of the fibrinolytic agent or as
a stand-alone procedure without using pharmaco-
logic thrombolytic agents [17, 18]. However, no da-
ta regarding their use for late thrombus removal af-
ter peripheral stent implantation are available.
Here we describe, for the first time, the efficacy
of percutaneous thrombectomy for treating acute pe-
ripheral nitinol-stent thrombosis, suggesting its use
not only in native arteries or aortic-coronary grafts,
but also in long-stented segment of SFA. The (An-
gioJet®) rheolytic thrombectomy (AngioJet®) sys-
tem has shown promising results in terms of safety
and efficacy to open thrombotic coronary arteries in
acute myocardial infarction, despite it has never
been tested in randomized trials. During ALI, the
rheolytic thrombectomy system has been shown to
be useful together with thrombolytic therapy in or-
der to re-establish blood flow into the native lower
extremity arteries [18]. Currently, it is not clear to
what extent this technique is applicable for periph-
eral stent thrombosis. Our reports indicate the effi-
cacy of this mechanical thrombus aspiration system
in SFA stent or PTFE prosthesis thrombosis. Indeed,
AngioJet® rheolytic thrombectomy has been effec-
tive in restoring immediate blood flow in stented
segment, supporting an efficacy and safety profile of
the Possis AngioJet cathetere and its use in patients
with peripheral acute stent-thrombosis. Thus, these
cases suggest that AngioJet® rheolytic thrombecto-
my might represent a novel effective strategy in the
percutaneous treatment of stent or graft thrombosis
determining ALI.
Riassunto
L’interruzione della terapia antiaggregante, de-
terminante trombosi degli stent in nitinol o dei by-pass
femoro-poplitei in politetrafluoroetilene (PTFE) della
femorale superficiale, costituisce una problematica
emergente nella gestione dei pazienti con ischemia
acuta dell’arto (ALI), che necessitano un intervento
immediato. Ad oggi, infatti, non esiste alcuna strate-
gia codificata per la gestione di queste complicanze.
Descriviamo di seguito due casi di ALI derivanti dal-
la interruzione della terapia antiaggregante con la
conseguente trombosi dello stent in nitinol, ed un ca-
so di ALI conseguente alla trombosi di un by-pass in
PTFE; in tutte le circostanze il salvataggio d’arto è
stato ottenuto rimuovendo il trombo attraverso trom-
bectomia percutanea di tipo reolitico (AngioJet®
rheolytic thrombectomy) e attuando una successiva
angioplastica transluminale percutanea (PTA). In tut-
ti i casi, è stato ottenuto un ottimo risultato angiogra-
fico. Ad oggi, i casi da noi descritti sono i primi in cui
è stato usato l’AngioJet® nel trattamento della ALI
Figure 3. - A-D: Complete occlusion of the superficial femoral artery, polytetrafluoroethylene (PTFE) femoro-popliteal bypass grafts and of the 
previously implanted stent at the distal end of the graft anastomosis. E-H: Slow flow and multiple minus images compatible with the presence of 
thrombi after Plain Old Balloon Angioplasty (POBA) at the proximal and distal anastomosis of bypass. I-N: Optimal angiographic result after thrombi
aspiration by AngioJet and stent implantation at the distal end of the anastomosis.
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dovuta a trombosi dello stent o del graft. Nell’insieme,
questi casi suggeriscono che la trombectomia percu-
tanea di tipo reolitico con AngioJet® costituisce una
valida alternativa nel trattamento della trombosi di
stent o graft, determinanti ALI.
ABBREVIATIONS LIST
ASA: Acetylsalicylic Acid
PAD: peripheral artery disease
SFA: superficial femoral arteries
ALI: acute limb ischaemia
RT: Rheolytic thrombectomy
PTCA: percutaneous transluminal coronary angioplasty
PTA: percutaneous transluminal angioplasty
PTFE, polytetrafluoroethylene
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